Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 16 September 1996
Length: 25 pages
Data source: Field research
Share a link:
https://casecent.re/p/46294
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
ImmuLogic Pharmaceutical Corp, a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by 'windows' for public offerings are highlighted.
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 13 pages
About
Abstract
ImmuLogic Pharmaceutical Corp, a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by 'windows' for public offerings are highlighted.
Settings
Related
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 13 pages